Literature DB >> 32725481

Sexually transmitted infections among adolescents with conduct disorder: a nationwide longitudinal study.

Yu-Tse Lin1,2, Ju-Wei Hsu1,2, Kai-Lin Huang1,2, Shih-Jen Tsai1,2, Tung-Ping Su1,2,3, Cheng-Ta Li1,2, Wei-Chen Lin1,2, Tzeng-Ji Chen4,5, Ya-Mei Bai6,7, Mu-Hong Chen8,9.   

Abstract

Studies have demonstrated that conduct disorder is related to risky sexual behaviors, the dominant risk factor for contracting a sexually transmitted infection (STI). However, the association between conduct disorder and STIs remains unclear. Using the Taiwan National Health Insurance Research Database, 5733 adolescents with conduct disorder and 22,932 age- and sex-matched controls without conduct disorder were enrolled from 2001 to 2009 and were subject to follow-up until the end of 2011. Participants who contracted any STI during the follow-up period were identified. Cox regression analysis was performed to examine the likelihood of subsequently contracting an STI for patients and controls. Patients with conduct disorder were more likely than controls to develop any STI (HR 3.95, 95% CI 2.97-5.26) after adjusting for demographic data, psychiatric comorbidities, and use of medications. Long-term use of second-generation antipsychotics (SGAs) was related to a reduced risk (HR 0.36, 95% CI 0.14-0.91) of developing an STI among patients with conduct disorder. Adolescents with conduct disorder had an increased risk of developing any STI later in life compared with those without conduct disorder. Long-term use of SGAs was associated with a lower risk of subsequent STI.
© 2020. Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Adolescents; Conduct disorder; Sexually transmitted infection

Year:  2020        PMID: 32725481     DOI: 10.1007/s00787-020-01605-5

Source DB:  PubMed          Journal:  Eur Child Adolesc Psychiatry        ISSN: 1018-8827            Impact factor:   4.785


  1 in total

Review 1.  Aripiprazole: a review of its pharmacology and clinical use.

Authors:  D M Taylor
Journal:  Int J Clin Pract       Date:  2003 Jan-Feb       Impact factor: 2.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.